Dec 15, 2020

Featuring a discussion of immune checkpoint inhibitors in urothelial bladder carcinoma with Dr Joaquim Bellmunt, including the following topics:

• Current clinical roles of atezolizumab and of pembrolizumab as first-line treatment for patients with metastatic urothelial bladder carcinoma (mUBC) (0:00)
• JAVELIN Bladder 100: Results of a Phase III trial evaluating first-line maintenance therapy with avelumab and best supportive care (BSC) versus BSC alone for patients with mUBC whose disease had not progressed after induction chemotherapy (12:07)
• Biologic rationale for combining enfortumab vedotin with pembrolizumab for patients with mUBC; available data with this combination (20:00)
• Case: A man in his mid-60s with mUBC, underlying immune disorders and disease progression on platinum-based therapy receives pembrolizumab (23:29)
• Case: A man in his mid-70s with mUBC experiences a complete response to first-line cisplatin/gemcitabine (28:04)

CME information and select publications